Plus Therapeutics Advances Radiotherapeutics in Q3 2024

Plus Therapeutics ( (PSTV) ) has released its Q3 earnings. Here is a breakdown of the information Plus Therapeutics presented to its investors.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for treating central nervous system cancers, leveraging advanced platform technologies and strategic partnerships to enhance clinical outcomes. The company recently released its third quarter 2024 financial results, highlighting significant progress in its clinical trials and strategic collaborations. Key developments include FDA approval to initiate a Phase 1 trial for Rhenium (186Re) Obisbemeda in patients with leptomeningeal metastases, and the presentation of positive trial data at the Congress of Neurological Surgeons Annual Conference. Additionally, Plus Therapeutics expanded its clinical trial sites and established a manufacturing partnership with SpectronRx to support future commercial needs. Financially, the company reported a net loss of $9.1 million for the year to date, reflecting increased research and development expenses, while maintaining a cash balance of $4.8 million. Moving forward, Plus Therapeutics remains focused on advancing its clinical programs and achieving key milestones in 2025, including launching new trials and expanding its diagnostic platform.